Thalidomide and metabolites: Indications of the absence of 'genotoxic' carcinogenic potentials

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 425, Issue 1, 1999, Pages 153-167

  Zhu, Xinyu ^a   Zhang, Ying Ping ^a   Klopman, Gilles ^b   Rosenkranz, Herbert S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Genotoxic; Metabolite; Thalidomide

Indexed keywords

DRUG METABOLITE; THALIDOMIDE;

ALGORITHM; AMES TEST; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; MODEL; MUTAGENICITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANIMALS; BIOTRANSFORMATION; CARCINOGENS; MICE; MUTAGENS; RATS; THALIDOMIDE;

EID: 0032997760     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(99)00035-4     Document Type: Article

References (79)

1. Moreira A.L., Corral L.G., Ye W., Johnson B., Stirling D., Muller G.W., Freedman V.H., Kaplan G. Thalidomide and thalidomide analogs reduce HIV type-1 replication in human macrophages in vitro. AIDS Res. Hum. Retroviruses. 13:1997;857-863.
2. Haslett P., Tramontana J., Burroughs M., Hempstead M., Kaplan G. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 24:1997;1223-1227.
3. Stirling D., Sherman M., Strauss S. Thalidomide. A surprising recovery. J. Am. Pharm. Assoc. 37:1997;306-313.
4. Shannon E.J., Sandoval F., Krahenbuhl J.L. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha. Immunopharmacology. 36:1997;9-15.
5. Zhu J., Bai X., Mix E., van der Meide P.H., Zwingenberger K., Link H. Thalidomide suppresses T- and B-cell responses to myelin antigen in experimental allergic neuritis. Clin. Neuropharmacol. 20:1997;152-164.
6. J.M. Jacobson, J.S. Greenspan, J. Spritzler, N. Ketter, J.L. Fahey, J.B. Jackson, L. Fox, M. Chernoff, A.W. Wu, L.A. MacPhail, G.J. Vasquez, D.A. Wohl, Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection, National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group, New Engl. J. Med. 336 (1997) 1487-1493.
7. Tavares J.L., Wangoo A., Dilworth P., Marshall B., Kotecha S., Shaw R.J. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir. Med. 91:1997;31-39.
8. Turk B.E., Jiang H., Liu J.O. Binding of thalidomide to alpha 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc. Natl. Acad. Sci. USA. 93:1996;7552-7556.
9. Lopez-Talavera J.C., Cadelina G., Olchowski J., Merrill W., Groszmann R.J. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 23:1996;1616-1621.
10. Klausner J.D., Makonkawkeyoon S., Akarasewi P., Nakata K., Kasinrerk W., Corral L., Dewar R.L., Lane H.C., Freedman V.H., Kaplan G. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 11:1996;247-257.
11. Tramontana J.M., Utaipart U., Molloy A., Akarasewi P., Burroughs M., Makonkawkeyoon S., Johnson B., Klausner J.D., Rom W., Kaplan G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1:1995;384-397.
12. S.G. Stolberg, 37 years later, a second chance for thalidomide, New York Times, September 23, 1997.
13. S.G. Stolberg, Thalidomide, once banned, is in demand, New York Times, November 28, 1997.
14. S.G. Stolberg, Thalidomide gets U.S. approval to aid lepers and maybe others, New York Times, July 17, 1998.
15. Castilla E.E., Ashton-Prolla P., Barreda-Mejia E., Brunoni D., Cavalcanti D.P., Correa-Neto J., Delgadillo J.L., Dutra M.G., Felix T., Giraldo A., Juarez N., Lopez-Camelo J.S., Nazer J., Orioli I.M., Paz J.E., Pessoto M.A., Pina-Neto J.M., Quadrelli R., Rittler M., Rueda S., Saltos M., Sanchez O., Schuler L. Thalidomide, a current teratogen in South America. Teratology. 54:1996;273-277.
16. S.G. Stolberg, Weighing hope against horror, New York Times, September 28, 1997.
17. Huang P.H., McBride W.G. Thalidomide-induced alteration in secondary structure of rat embryonic DNA in vivo. Teratog. Carcinog. Mutag. 10:1990;281-294.
18. 14C ]-thalidomide with rat embryonic DNA in vivo Teratog. Carcinog. Mutag. 17:1997;1-5.
19. Ashby J., Tinwell H. Is thalidomide mutagenic? Nature. 375:1995;453.
20. Ashby J. Thalidomide is not a mutagen. Nature. 389:1997;118.
21. Neubert D. Never-ending tales of the mode of the teratogenic action of thalidomide. Teratog. Carcinog. Mutag. 17:1997;1-2.
22. Smithells R.W. Thalidomide may be a mutagen. Br. Med. J. 309:1994;477.
23. Read A.P. Thalidomide may be a mutagen. Br. Med. J. 308:1994;1636.
24. McBride W.G. Thalidomide may be a mutagen. Br. Med. J. 308:1994;1635-1636.
25. Ennever F.K., Noonan T.J., Rosenkranz H.S. The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis. 2:1987;73-78.
26. Bartsch H., Malaveille C. Prevalence of genotoxic chemicals among animal and human carcinogens evaluated in the IARC Monograph Series. Cell Biol. Toxicol. 5:1989;115-127.
27. Shelby M.D. The genetic toxicity of human carcinogens and its implications. Mutat. Res. 204:1988;3-15.
28. Ashby J., Morrod R.S. Detection of human carcinogens. Nature. 352:1991;185-186.
29. Ashby J., Tinwell H., Callander R.D., Kimber I., Clay P., Galloway S.M., Hill R.B., Greenwood S.K., Gaulden M.E., Ferguson M.J., Vogel E., Nivard M., Parry J.M., Williamson J. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutat. Res. 396:1997;45-64.
30. Bishop J.B., Witt K.L., Sloane R.A. Genetic toxicities of human teratogens. Mutat. Res. 396:1997;9-43.
31. Klopman G. Artificial intelligence approach to structure-activity studies. Computer-automated structure evaluation of biological activity of organic molecules. J. Am. Chem. Soc. 106:1984;7315-7321.
32. Klopman G. MULTICASE 1. A hierarchical computer-automated structure evaluation program. Quant. Struct.-Act. Relatsh. 11:1992;176-184.
33. Klopman G., Rosenkranz H.S. Prediction of carcinogenicity/mutagenicity using MULTICASE. Mutat. Res. 305:1994;33-46.
34. Chankong V., Haimes Y.Y., Rosenkranz H.S., Pet-Edwards J. The carcinogenicity prediction and battery selection (CPBS) method: a Bayesian approach. Mutat. Res. 153:1985;135-166.
35. Zhang Y.P., Sussman N., Macina O.T., Rosenkranz H.S., Klopman G. Prediction of the carcinogenicity of a second group of chemicals undergoing carcinogenicity testing. Environ. Health Perspect. 104:1996;1045-1050. Suppl. 5.
36. O.T. Macina, Y.P. Zhang, H.S. Rosenkranz, Improved predictivity of chemical carcinogens: the use of a battery of SAR models. in: K.T. Kitchin (Ed.), Carcinogenicity: Testing, Predicting and Interpreting Chemical Effects, (1998) 227-250.
37. Liu M., Sussman N., Klopman G., Rosenkranz H.S. Estimation of the optimal database size for structure-activity analyses: the Salmonella mutagenicity database. Mutat. Res. 358:1996;63-72.
38. Zeiger E., Ashby J., Bakale G., Enslein K., Klopman G., Rosenkranz H.S. Prediction of Salmonella mutagenicity. Mutagenesis. 11:1996;471-484.
39. Rosenkranz H.S., Klopman G. The structural basis of the mutagenicity of chemicals in Salmonella typhimurium: The National Toxicology Program database. Mutat. Res. 228:1990;51-80.
40. Dunkel V., Zeiger E., Brusick D., McCoy E.C., McGregor D., Mortelmans K., Rosenkranz H.S., Simmon V.F. Reproducibility of microbial mutagenicity assays: I. Tests with Salmonella typhimurium and Escherichia coli using a standard protocol. Environ. Mutagen. 6:1984;1-251. Suppl. 2.
41. Dunkel V.C., Zeiger E., Brusick D., McCoy E., McGregor D., Mortelmans K., Rosenkranz H.S., Simmon V.F. Reproducibility of microbial mutagenicity assays: II. Testing of carcinogens and non-carcinogens in Salmonella typhimurium and Escherichia coli. Environ. Mutagen. 7:1985;1-248. Suppl. 5.
42. Mortelmans K., Haworth S., Lawlor T., Speck W.T., Tainer B., Zeiger E. Salmonella mutagenicity tests. II. Results from the testing of 270 chemicals. Environ. Mutagen. 8:1986;1-119.
43. Zeiger E. Carcinogenicity of mutagens: predictive capability of the Salmonella mutagenesis assay for rodent carcinogenicity. Cancer Res. 47:1987;1287-1296.
44. Zeiger E., Anderson B., Haworth S., Lawlor T., Mortelmans K., Speck W. Salmonella mutagenicity tests: III. Results from 255 chemicals. Environ. Mutagen. 9:1987;1-109. Suppl. 9.
45. Zeiger E., Anderson B., Haworth S., Lawlor T., Mortelmans K. Salmonella mutagenicity tests: IV. Results from the testing of 300 chemicals. Environ. Mol. Mutagen. 11:1988;1-157. Suppl. 12.
46. Ashby J., Tennant R.W. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP. Mutat. Res. 257:1991;229-306.
47. Rosenkranz H.S., Klopman G. Structural basis of carcinogenicity in rodents of genotoxicants and non-genotoxicants. Mutat. Res. 228:1990;105-124.
48. Rosenkranz H.S., Zhang Y.P., Klopman G. Risk identification using structural concepts: the potential carcinogenicity of praziquantel. Regul. Toxicol. Pharmacol. 22:1995;152-161.
49. Rosenkranz H.S., Cunningham A., Klopman G. Identification of a 2-D geometric descriptor associated with non-genotoxic carcinogens and some estrogens and antiestrogens. Mutagenesis. 11:1996;95-100.
50. Gold L.S., Sawyer C.B., Magaw R., Backman G.M., de Veciana M., Levinson R., Hooper N.K., Havender W.R., Bernstein L., Peto R., Pike M.C., Ames B.N. A carcinogenic potency database of the standardized results of animal bioassays. Environ. Health Perspect. 58:1984;9-319.
51. Gold L.S., de Veciana M., Backman G.M., Magaw R., Lopipero P., Smith M., Blumenthal M., Levinson R., Bernstein L., Ames B.N. Chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1982. Environ. Health Perspect. 67:1986;161-200.
52. Gold L.S., Slone T.H., Backman G.M., Magaw R., Da Costa M., Lopipero P., Blumenthal M., Ames B.N. Second chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986. Environ. Health Perspect. 74:1987;237-329.
53. Gold L.S., Slone T.H., Backman G.M., Eisenberg S., DaCosta M., Wong M., Manley N.B., Rohrbach L., Ames B.N. Third chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1986 and by the National Toxicology Program through June 1987. Environ. Health Perspect. 84:1990;215-286.
54. Gold L.S., Manley N.B., Slone T.H., Garfinkel G.B., Rohrbach L., Ames B.N. The fifth plot of the carcinogenic potency database: results of animal bioassays published in the general literature through 1988 and by the National Toxicology Program through 1989. Environ. Health Perspect. 100:1993;65-135.
55. Cunningham A., Klopman G., Rosenkranz H.S. A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites. Mutat. Res. 349:1996;85-94.
56. Cunningham A., Klopman G., Rosenkranz H.S. The carcinogenicity of diethylstilbestrol: structural evidence for a non-genotoxic mechanism. Arch. Toxicol. 70:1996;356-361.
57. Cunningham A.R., Rosenkranz H.S., Zhang Y.P., Klopman G. Identification of 'genotoxic' and 'non-genotoxic' alerts for cancer in mice: the carcinogenicity potency database. Mutat. Res. 398:1998;1-17.
58. Ghanooni M., Mattison D.R., Zhang Y.P., Macina O.T., Rosenkranz H.S., Klopman G. Structural determinants associated with risk of human developmental toxicity. Am. J. Obstet. Gynecol. 176:1997;799-806.
59. Klopman G., Dimayuga M., Talafous J. META: 1. A program for the evaluation of metabolic transformation of chemicals. J. Chem. Inf. Comput. Sci. 34:1994;1320-1325.
60. Talafous J., Sayre L.M., Mieyal J.J., Klopman G. META: 2. A dictionary model of mammalian xenobiotic metabolism. J. Chem. Inf. Comput. Sci. 34:1994;1326-1333.
61. Klopman G., Zhang Z., Balthasar D.M., Rosenkranz H.S. Computer-automated prediction of aerobic biodegradation transformation in the environment. Environ. Toxicol. Chem. 14:1995;395-403.
62. Braun A.G., Weinreb S.L. Teratogen metabolism: activation of thalidomide and thalidomide analogues to products that inhibit the attachment of cells to concanavalin A-coated plastic surfaces. Biochem. Pharmacol. 33:1984;1471-1477.
63. Rosenkranz H.S., Zhang Y.P., Klopman G. Studies on the potential for genotoxic carcinogenicity of fragrances and other chemicals. Food Chem. Toxicol. 36:1998;687-696.
64. Fabro S., Schumacher H., Smith R.L., Stagg R.B.L., Williams R.T. The metabolism of thalidomide: some biological effects of thalidomide and its metabolites. Br. J. Pharmacol. 25:1965;352-362.
65. Schumacher H., Smith R.L., Williams R.T. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 25:1965;324-337.
66. Schumacher H., Smith R.L., Williams R.T. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25:1965;338-351.
67. 14C ] thalidomide in the pregnant rabbit Biochem. J. 104:1967;565-569.
68. Fabro S., Smith R.L., Williams R.T. The fate of the hydrolysis products of thalidomide in the pregnant rabbit. Biochem. J. 104:1967;570-574.
69. Champy-Hatem P.S. Action de l'imidazole sur les premiers métabolites de la thalidomide. Arzneim.-Forsch. 15:1965;508-512.
70. Meise W., Köhler F. Embryotoxische Aktivität ron N-phthaloyl-DL-isoglutamin. Z. Naturforsch. 26:1971;1081-1082.
71. Braun A.G., Dailey J.P. Thalidomide metabolite inhibits tumor cell attachment to concanavalin A-coated surfaces. Biochem. Biophys. Res. Commun. 98:1981;1029-1034.
72. Weinz C., Blaschke G. Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis. J. Chromatogr. B. 674:1995;287-292.
73. Gordon G.B., Spielberg S.P., Blake D.A., Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. USA. 78:1981;2545-2548.
74. Tanaka A., Hasegawa A., Urakubo G. Metabolic fate of thalidomide in rats. Chem. Pharm. Bull. 13:1965;1263-1265.
75. Meise W., Ockenfels H., Köhler F. Teratologische prüfung der hydrolysenprodukte des thalidomids. Experientia. 29:1993;423-424.
76. Ockenfels H., Köhler F. Das L-isomere als teratoŸenes Prinzip der N-phthalyl-DL-glutamininsäure. Experientia. 15:1970;1236-1237.
77. H.S. Rosenkranz, From mutagen hunter to genome defender: a change in paradigm. Mutat. Res. (1999) in press.
78. E.J. Matthews, J.F. Contrera, A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCCASE QSAR-ES software. Regul. Toxicol. Pharmacol. (1999) in press.
79. P. Galewitz, Infamous drug is making a comeback. Associated Press (1999).